![The breaking news round-up: Decagear launches today, Pimax announces new headsets, and more! [APRIL FOOL’S]](https://i0.wp.com/skarredghost.com/wp-content/uploads/2025/03/lawk_glasses_handson.jpg?fit=1366%2C1025&ssl=1)
Lilly says further head-to-head trial data back Zepbound over Novo’s Wegovy
Eli Lilly said Sunday that new data on Zepbound show the GIP/GLP-1 dual agonist is a better weight loss drug than Novo Nordisk’s Wegovy. Almost 65% of obese or overweight people treated with Zepbound in ...
Eli Lilly said Sunday that new data on Zepbound show the GIP/GLP-1 dual agonist is a better weight loss drug than Novo Nordisk’s Wegovy.
Almost 65% of obese or overweight people treated with Zepbound in ...
